TITLE

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

AUTHOR(S)
LIPSKA, KASIA J.; BAILEY, CLIFFORD J.; INZUCCHI, SILVIO E.
PUB. DATE
June 2011
SOURCE
Diabetes Care;Jun2011, Vol. 34 Issue 6, p1431
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on the use of metformin in patients with renal insufficiency. It cites the advantages of metformin including reduced cardiovascular morbidity and total mortality in newly diagnosed type 2 diabetic patients. Metformin was developed for lowering glucose in the 1950s and belongs to the biguanide drug class. Also included are clinical practice guidelines, its pharmacokinetics, the use of metformin in chronic kidney disease (CKD), and progression of CKD in diabetics.
ACCESSION #
65099021

 

Related Articles

  • Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. Viazzi, Francesca; Greco, Eulalia; Ceriello, Antonio; Fioretto, Paola; Giorda, Carlo; Guida, Pietro; Russo, Giuseppina; De┬áCosmo, Salvatore; Pontremoli, Roberto // Kidney & Blood Pressure Research;Jun2018, Vol. 43 Issue 2, p422 

    Background/Aims: Apparent treatment resistant hypertension (aTRH) is highly prevalent in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The impact of aTRH and achievement of recommended blood pressure (BP) values on the rate of glomerular...

  • Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study. Chen, Yu-Hsin; Chiang, Ming-Han; Liu, Jia-Sin; Chang, Yu-Kang; Kuo, Ko-Lin; Hung, Szu-Chun; Tai, Hsin-Ling; Hsu, Chih-Cheng; Tarng, Der-Cherng // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Thiazolidinediones (TZDs) reduce urinary albumin excretion and proteinuria in diabetic nephropathy. The effect of TZDs on hard renal outcome in diabetic patients with chronic kidney disease (CKD) is unknown. We investigate the association of TZDs and risk of long-term dialysis or death in...

  • Management of Hyperglycemia in Diabetic Kidney Disease. Neumiller, Joshua J.; Hirsch, Irl B. // Diabetes Spectrum;Summer2015, Vol. 28 Issue 3, p214 

    The article discusses various factors responsible for the management of glycemia in patients with chronic kidney disease (CKD) including approximated testing of hemoglobin A1C in people with CKD and antidiabetic medication adjustment. The various antidiabetic medicines used for controlling CKD...

  • Is it time to increase access to transplantation for those with diabetic end-stage kidney disease? Chadban, Steven J; Staplin, Natalie D // Kidney International;Sep2014, Vol. 86 Issue 3, p464 

    Keddis et al. present a large, single-center experience that demonstrates improvement over time in survival of patients with diabetes and end-stage kidney disease who receive a kidney transplant. We discuss how these data should prompt transplant programs to consider providing greater access to...

  • Nutrition Intervention for Advanced Stages of Diabetic Kidney Disease. Goldstein-Fuchs, Jordi; Kalantar-Zadeh, Kamyar // Diabetes Spectrum;Summer2015, Vol. 28 Issue 3, p181 

    The article discusses dietary intake for controlling diabetic kidney disease (DKD) and examination of dietary intake patterns in people with DKD. The various dietary intakes that have shown effects in maintaining nutritional status in DKD patients includes dietary proteins, consumption of...

  • Transcriptome-Based Analysis of Kidney Gene Expression Changes Associated with Diabetes in OVE26 Mice, in the Presence and Absence of Losartan Treatment. Komers, Radko; Xu, Bei; Fu, Yi; McClelland, Aaron; Kantharidis, Phillip; Mittal, Amit; Cohen, Herbert T.; Cohen, David M. // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Diabetes is among the most common causes of end-stage renal disease, although its pathophysiology is incompletely understood. We performed next-generation sequencing-based transcriptome analysis of renal gene expression changes in the OVE26 murine model of diabetes (age 15 weeks), relative to...

  • Baxter's Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of Diabetics Undergoing Dialysis.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article informs that Baxter International Inc. has released results from two clinical trials evaluating the potential of low glucose peritoneal dialysis (PD) regimen end-stage renal disease (ESRD) patients with diabetes. It also informs that results were presented as the 49th Annual European...

  • Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus. Roumie, Christianne L.; Hung, Adriana M.; Greevy, Robert A.; Grijalva, Carlos C.; Xulei Liu; Murff, Harvey J.; Elasy, Tom A.; Griffin, Marie R. // Annals of Internal Medicine;11/6/2012, Vol. 157 Issue 9, p601 

    Background: The effects of sulfonylureas and metformin on out-comes of cardiovascular disease (CVD) in type 2 diabetes are not well-characterized. Objective: To compare the effects of sulfonylureas and metformin on CVD outcomes (acute myocardial infarction and stroke) or death. Design:...

  • Metformin.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p145 

    The article presents a case study of a 77 year old woman with chronic kidney disease (CKD) and diabetes who is diagnosed with lactic acidosis caused by metformin therapy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics